A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

Active:	Yes
Cancer Type:	Solid Tumor	NCT ID:	NCT06208878
Trial Phases:		Protocol IDs:	CRSP-ONC-LTF (primary) NCI-2024-01163
Eligibility:	18 Years and older, Male and Female	Study Type:	Other
Study Sponsor:	CRISPR Therapeutics AG
NCI Full Details:	http://clinicaltrials.gov/show/NCT06208878

Summary

This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular
therapies

Objectives

All subjects with hematological and solid malignancies who are enrolled in a parent study
and were exposed to allogeneic CRISPR CAR T cellular therapy will be asked to participate
in this long-term follow-up (LTFU) study. Subjects who have completed the parent study
for the protocol-defined duration, or who have discontinued the parent study early, or
who are in secondary follow-up (follow up of subjects with progressive disease or who
receive a subsequent line of anticancer therapy) in the parent study may enroll in this
LTFU study. This will allow for collection of long-term efficacy data (as applicable) and
safety data up to 15 years post-treatment with CRISPR CAR T cellular therapies.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.